Navigation Links
Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
Date:1/8/2008

>

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech is creating technologies that enable the delivery of peptide and protein therapeutics without the requirement of an injection, which is currently the most common form of administration for this class of drugs. Nastech has also established a wholly-owned subsidiary, MDRNA, Inc., to focus on developing RNA-based technologies and therapeutics. MDRNA is harnessing the power of RNA interference, a cellular mechanism that can turn off the production of a specific protein through use of small interfering RNAs (siRNAs), to develop a new class of therapeutics by identifying key protein targets, designing the siRNAs that will turn off the production of the targeted proteins, and creating a formulation for the delivery of the therapeutics. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. For additional information about Nastech please visit http://www.nastech.com.

Nastech Forward Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech or a subsidiary to obtain additional funding; (ii) the ability of Nastech or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Nastech, a subsidiary and/or a partner to successfully complete product research and dev
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
2. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
3. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... BOULDER, Colo. , April 27, 2015 ... will report financial results for the third ... conference call to discuss those results on ... Executive Officer will lead the call.Date:Monday, May ... Code: 5249676 Webcast, including Replay and Conference ...
(Date:4/27/2015)... Inc. (NYSE: CRY ), a leading medical device ... surgery, announced today that it has received a close-out ... ("FDA") verifying that the Company has successfully implemented corrective ... received from the FDA in January 2013. ... by the FDA at CryoLife,s manufacturing facility and headquarters ...
(Date:4/27/2015)... NEW YORK , April 27, 2015   ... management solutions, will showcase advances in monitored care that ... the upcoming ATA 2015 Conference, May 2-5 ... Center. AMC Health will share information about ... monitored care to help transform and personalize healthcare delivery ...
Breaking Medicine Technology:CryoLife Announces Resolution of FDA Warning Letter 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4
... DIEGO, Oct. 13 RESMED INC. (NYSE: RMD ... will release its results for the first quarter of fiscal ... ResMed,s results will be issued after 1:00 p.m. Pacific Time ... to review its results, market trends, and future outlook. ...
... Care Continuum Alliance honored Kaiser Permanente,s ALL/PHASE initiative ... on Health" at The Forum 10 conference ... low-cost and generic medications and clinical interventions to reduce ... communities, including those served by safety net organizations. ...
Cached Medicine Technology:ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 3
(Date:4/27/2015)... VA (PRWEB) April 27, 2015 A new ... on Saturday, May 9. Science on Tap at the Science ... favorite local brews, but adds science hops for a bold, ... music, food trucks and serves up the science behind these ... Homebrewers, get a first-hand look at the ingredients that go ...
(Date:4/27/2015)... UC Davis investigators have settled ... an inherited disorder that historically affected Ashkenazi Jews ... other populations of Semitic descent, particularly families from ... experiments, the researchers uncovered the biochemical underpinnings of ... an incurable and progressively fatal neurological condition. The ...
(Date:4/27/2015)... 27, 2015 Diamond reflective technology has ... of damaging hot spots. , Gorilla Grow Tents stand ... their sturdy structure and strong material that is lined ... to effectively distribute lumens and eliminates hot spots. ... from grow lights and produces the highest yield. The ...
(Date:4/27/2015)... April 27, 2015 Thanks to a ... researchers from a half-dozen institutions, including American University, will ... basic and social and behavioral research aimed at ending ... residents are living with HIV or AIDS, according to ... percent of D.C.'s population over the age of 13 ...
(Date:4/27/2015)... Guided by the extensive work of its community ... collaboration with organizations around the world to identify proven ... essential actions for organizations committed to patient experience ... systems committed to providing the best in experience will:, ... with committed time and focused intent to shape and ...
Breaking Medicine News(10 mins):Health News:Science on Tap at the Science Museum of Virginia 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 3Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 4Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2
... While scientists and physicians know what happens if you don,t ... have long been puzzled about what controls the actual need ... Medicine might have an answer, at least in fruit flies. ... gene that controls sleep. , "We spend -- or ...
... Klein, former SVP Corporate Officer of Gillette, brings 38 years ... experience in consumer products ... leading,strategy consulting group, announced today that Peter Klein has joined ... of experience in the global consumer products,industry and was most ...
... problems may leave a mark on the brain, by ... sleep and problems with attention. For one in six ... that often trigger more frequent urges to urinate, such ... , "We often tend to focus on just ...
... friends and neighbors remember Lisa Sandler Spaeth as an ... lot on the go, juggling her son,s baseball games ... organizing women,s activities at her local synagogue. Add ... - making custom hair accessories for children - which ...
... must pass legislation to give FDA needed regulatory ... The following is a,statement by Ron Davis, M.D., ... the U.S. House of Representatives must take a ... ,Family Smoking and,Tobacco Control Act, and giving the ...
... 29 The Los Angeles Jewish Home,s,prestigious new Annenberg ... its second session as one of the only U.S. ... The Annenberg School of Nursing offers a full-time program ... for licensure. The,intensive vocational nursing program engages students 40 ...
Cached Medicine News:Health News:Searching for shut eye: Penn study identifies possible sleep gene 2Health News:The Cambridge Group Names Peter Klein a Director 2Health News:Findings on bladder-brain link may point to better treatments for problems in sleep, attention 2Health News:Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in 2Health News:Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in 3Health News:Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in 4Health News:Los Angeles Jewish Home's New Annenberg School of Nursing Seeks Applicants for Second Session of Precedent-Setting U.S. Senior-Care Facility's School of Nursing 2Health News:Los Angeles Jewish Home's New Annenberg School of Nursing Seeks Applicants for Second Session of Precedent-Setting U.S. Senior-Care Facility's School of Nursing 3
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
... Type 14, 14A and 14C have been approved. ... to accommodate the variations in the size of ... tension rings are designed to stabilize the capsule ... large panel of U.S. ophthalmologists. For implatations ...
... is a device designed for permanent implantation ... removal surgery. It provides secondary capsular bag ... The CTR is a uniplanar, 270-degree, semi-circle ... absorbing polymethylmethacrylate (PMMA) with one manipulation eyelet ...
Stainless steel cartilage scissors....
Medicine Products: